DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026)
DiaMedica Therapeutics (DMAC) reported Total Non-Current Liabilities of $97000.0 for Q1 2026, down 54.03% on a YoY basis from $211000.0 in Q1 2025, and down 24.22% quarter-over-quarter from $128000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics has reported Total Non-Current Liabilities for 9 years, with the latest figure at $97000.0 in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 54.03% year-over-year to $97000.0; the trailing twelve-month figure through Mar 2026 stood at $97000.0 (down 54.03% YoY), and the FY2025 full-year result was $128000.0, down 45.99% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $97000.0, down from $128000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $420000.0 in Q3 2022, with the low at $7000.0 in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $240823.5 across 5 years, with a median of $263000.0 in 2024.
- The largest YoY upside for Total Non-Current Liabilities was 13233.33% in 2022 against a maximum downside of 72.73% in 2022.
- DiaMedica Therapeutics' Total Non-Current Liabilities stood at $400000.0 in 2022, then slipped by 20.75% to $317000.0 in 2023, then declined by 25.24% to $237000.0 in 2024, then plunged by 45.99% to $128000.0 in 2025, then retreated by 24.22% to $97000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $97000.0 (Q1 2026), $128000.0 (Q4 2025), and $157000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - | 97,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Dec 31, 2023 | 317,000.00 |
| Sep 30, 2023 | 340,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 381,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 16,000.00 |